Diphtheria
Therapeutic area
Infectious Disease
Rare disease
Yes
- Definition
- A Gram-positive bacterial infection caused by Corynebacterium diphtheriae. It usually involves the oral cavity, pharynx, and nasal cavity. Patients develop pseudomembranes in the affected areas and manifest signs and symptoms of an upper respiratory infection. The diphtheria toxin may cause myocarditis, polyneuritis, and other systemic effects.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Diphtheria
- Alternative names
- diphtheria
- Therapeutic area
- Infectious Disease
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Severe
- MONDO ID
- MONDO:0005504
- Parent condition
- MONDO:0000314
Related records
Broader conditions (7)
- Bacterial infectious disease
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Primary bacterial infectious disease
Narrower conditions (7)
- Anterior nasal diphtheria
- Cutaneous diphtheria
- Diphtheritic myocarditis
- Faucial diphtheria
- Laryngeal diphtheria
- Nasopharyngeal diphtheria
- Pseudomembranous diphtheritic conjunctivitis
Trials (254)
- A Clinical Study on Immunogenicity Persistence of Adsorbed 5-component Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine
- A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)
- A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
- A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)
- A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
- A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
- A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
- A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
- A Phase IV Study to Assess the Safety of EupentaTM Inj
- A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
- A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays
- A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
- A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants
- A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants
- A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)
- A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
- A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women
- A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.
- A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
Approved drugs (1)
Drugs in development (1)
- Sodium chloride Phase 1
Other linked drugs (4)
- Bordetella pertussis filamentous hemagglutinin
- Bordetella pertussis pertactin autotransporter
- Diphtheria toxoid
- Tetanus toxoid